Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-X by engaging a single-residue discrepancy.
Overexpressed pro-survival B-cell lymphoma-2 (BCL-2) family proteins BCL-2 and BCL-X can render tumor cells malignant. Leukemia drug venetoclax is currently the only approved selective BCL-2 inhibitor. However, its application...
Read More